Revenue rose 2.36% to RMB 40.03 billion and net profit jumped 16.02% to RMB 4.75 billion, with strong growth in core pharmaceutical and health product segments. Cash dividend payout reached 90% of net profit, and the company advanced digital transformation and R&D investment.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.